SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001213900-23-009695
Filing Date
2023-02-09
Accepted
2023-02-09 15:02:20
Documents
66
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT f10k2022_rasnathera.htm   iXBRL 10-K 1046581
2 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARB f10k2022ex31-1_rasnathera.htm EX-31.1 11723
3 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARB f10k2022ex31-2_rasnathera.htm EX-31.2 11586
4 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 CERTIFICATI f10k2022ex32-1_rasnathera.htm EX-32.1 4147
5 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 CERTIFICATI f10k2022ex32-2_rasnathera.htm EX-32.2 4161
  Complete submission text file 0001213900-23-009695.txt   4795677

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE rasp-20220930.xsd EX-101.SCH 58355
7 XBRL CALCULATION FILE rasp-20220930_cal.xml EX-101.CAL 26740
8 XBRL DEFINITION FILE rasp-20220930_def.xml EX-101.DEF 219022
9 XBRL LABEL FILE rasp-20220930_lab.xml EX-101.LAB 486690
10 XBRL PRESENTATION FILE rasp-20220930_pre.xml EX-101.PRE 235797
60 EXTRACTED XBRL INSTANCE DOCUMENT f10k2022_rasnathera_htm.xml XML 443633
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-K | Act: 34 | File No.: 333-191083 | Film No.: 23605751
SIC: 2834 Pharmaceutical Preparations